Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus toripalimab with chemotherapy or with trastuzumab as first-line treatment for advanced or metastatic gastric/GEJ adenocarcinoma
CTR20231605Phase 2Active
- Sponsor
- RemeGen
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, toripalimab, trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Aug 2023; status: active.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20231605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231605.